Allogene Q2 Cash Tops $300 Million
Allogene Therapeutics (NASDAQ:ALLO) reported second-quarter 2025 results on August 13, 2025, highlighting $302.6 million in cash and investments as of the end of Q2 2025 with a projected cash runway into the second half of 2027 despite reporting a GAAP net loss of $50.9 million. The company streamlined the pivotal ALPHA-three trial, advanced the ALLO-316 solid tumor program with FDA alignment, and initiated the ALLO-329 autoimmune study, signaling critical strategic inflection points for its allogeneic CAR T cell pipeline. The following analysis dissects these developments and their implications for long-term investors.
Protocol amendments eliminated the enhanced lymphodepletion (FCA) arm, leaving a two-arm randomized study and prioritizing patient safety and operational scalability. Over 50 sites are now active for ALPHA-three enrollment, and feedback indicates increased investigator engagement following this design change.
This decisive protocol alteration reduces operational complexity, lowers clinical risk, and is likely to accelerate enrollment while removing exposure to ALLO-647–related adverse events in front-line large B-cell lymphoma patients.
Source Fool.com
